Peptide Production: HHS grants compounding pharmacies new enforcement discretion
Six unproven wellness compounds may now be made by small pharmacies, though experts warn supply will be limited and safety evidence remains sparse.
By Matthew Qureshi ·
The U.S. Department of Health and Human Services issued a new policy on Tuesday that allows small compounding pharmacies to produce six specific peptides. These compounds have long been sold on the gray market despite a formal ban, but they have not undergone the rigorous review and approval process required by the Food and Drug Administration.
The administration has been working to regulate these substances for several months. In July, an advisory panel to the FDA voted in favor of expanding access to these six peptides through compounding pharmacies. At that same meeting, FDA scientists recommended against lifting existing restrictions, citing a lack of sufficient evidence for safety and effectiveness.
Health Secretary Robert F. Kennedy Jr., a vocal supporter of peptides who has used some personally, announced the new enforcement discretion. The policy specifically targets 503A compounding pharmacies, which produce smaller quantities of medicine. It does not apply to 503B outsourcing facilities that produce higher volumes, meaning large-scale production remains restricted under current rules.
The six peptides covered by the policy include BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500. Proponents often cite uses ranging from treating ulcerative colitis and insomnia to aiding wound healing and metabolic health. The HHS states that compounding is a safer alternative to illicit "research-use-only" peptides, which are frequently sourced from overseas suppliers of questionable reliability.
Joshua Fritzler, president of Olympia and Wesley Pharmaceuticals in central Florida, said his company has received requests for these compounds for years but could not legally manufacture them before. Under the new rules, his smaller facility can produce the peptides, but only in limited amounts. "We won't be able to meet demand," Fritzler said, noting that his company will likely focus on just one of the six initially.
Scott Brunner, CEO of the Alliance for Pharmacy Compounding, called the decision a welcome move. He said the policy brings patients into a system with pharmacy standards and regulatory oversight. However, he warned that it may take time for pharmacies to begin dispensing the products, as suppliers must first verify that their active ingredients meet the new policy requirements.
Consumer advocacy groups expressed concern about the shift. Dr. Robert Steinbrook of Public Citizen argued that Kennedy acted unilaterally rather than following the standard rulemaking process. Shabbir Safda, executive director of the Partnership for Safe Medicines, noted that the group filed a petition last week urging the FDA to ignore the July advisory vote. "Today's decision leaves Americans in a grey area as to whether peptides are safe or not," Safda said.
